Slide 1: Introduction to Personalis
Introduction to Personalis Revolutionizing Cancer Management with Early Recurrence Detection and Personalized Therapies August 2026 © 2026 Personalis, Inc. All rights reserved. All trademarks a re the property of Personalis, Inc. or their respective owners. All products described here are for Resear
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements and implied expectations or results other than statements of historical fact contained in this presenta
Slide 3: The Future of Cancer Management is Here
The Future of Cancer Management is Here Cancer treatment has improved, but today’s “best practices” fall short in two critical ways. Treating each Detecting if cancer patient’s unique has returned, much cancer, uniquely. sooner. Our patented innovations redefine best practices that will transform li
Slide 4: Our Vision
OUR VISION Cancer care that harnesses the unique biology of each patient to detect cancer earlier and treat it more effectively. | Personalis, Inc. | Confidential and Proprietary 4
Slide 5: Our Technology Led to the Launch of Four Industry Leading Products
Our Technology Led to the Launch of Four Industry Leading Products Advanced Tumor Profiling Precise Genetic Analysis Optimizing patient selection for Revealing the unique genetic drug trials signatures of solid tumors Personalized Cancer Therapies Early Recurrence Detection Enabling biotech partners
Slide 6: Those Products Fuel a Growing Business
Those Products Fuel a Growing Business Increasing Clinical Test We Know the Medicare Volume Process Growing Test Volume 37,000+ Tests + Medicare Reimbursement Delivered 10,384 clinical tests in NeXT Personal Dx (MRD1) is Q2-2026 and more than 37,000 approved for Medicare = tests to date reimbursemen
Slide 7: Our Technology Has Robust Legal Protection
Our Technology Has Robust Legal Protection More than 70 patents world-wide 2024 Myriad agreement provides non-exclusive access to all Myriad IP for cancer recurrence blood 38 testing, strengthening our US Patents market position | Personalis, Inc. | Confidential and Proprietary 77
Slide 8: Early Detection Matters
Early Detection Matters Patients face agonizing uncertainty about cancer recurrence. Personalis offers answers sooner. Is my cancer gone? Do I need different therapies? Will we catch it in time if it returns? | Personalis, Inc. | Confidential and Proprietary 8
Slide 9: Introducing NeXT Personal Dx
Introducing Clinically available “ultra-sensitive” test that detects tiny tumor pieces in the blood, earlier than ever before. Tumors shed tiny pieces of NeXT Personal Dx can Healthcare providers can act cancer DNA into the blood. reliably detect tiny DNA earlier, when it matters most. fragments wit
Slide 10: NeXT Personal Dx Provides "1-in-a-Million" Personalized Cancer Detection
NeXT Personal Dx Provides “1-in-a-Million” Personalized Cancer Detection ~ 1800 unique DNA markers We analyze each patient’s solid tumor. We identify up to ~ 1800 unique NeXT Personal Dx detects even 1 DNA markers present in the tumor cancerous tumor~fragment in a million but not healthy blood. norm
Slide 11: What NeXT Personal Dx Means for Patients and Physicians
What NeXT Personal Dx Means for Patients and Physicians Periodic imaging requires longer waits for answers. While Imaging is vital, it often Patients with solid tumors wait NeXT Personal Dx blood tests offer patients detects recurrence later than months for periodic imaging and doctors an easy, reli
Slide 12: Strong Clinical Evidence for NeXT Personal Dx
Strong Clinical Evidence for NeXT Personal Dx consistently detects cancer recurrence and progression earlier than scans Colorectal Cancers Lung Cancers 6 months earlier* 5 months earlier* Breast Cancers Cervical Cancers 15 months earlier* 5 months earlier* *Approximate Median Lead Time Ahead of Imag
Slide 13: 2026: Marketplace Success - Accelerating NeXT Personal Growth
2026: Marketplace Success - Accelerating NeXT Personal Growth Focused Evidence Expansion Business Catalysts Expanding clinical evidence: Additional Medicare coverage drives Studies in breast, colorectal and future revenue growth and gross lung cancer, and immunotherapy margin expansion. monitoring.
Slide 14: Driving Clinical Test Volume Growth with MRD
Driving Clinical Test Volume Growth with MRD Includes all molecular tests (NeXT Personal Dx & NeXT Dx) “Win-in-MRD” with high growth Q2 Sequential 33% quarter growth 10,384 Q2 test volume Tests delivered >37,000 to date | Personalis, Inc. | Confidential and Proprietary 14
Slide 15: Proven Leadership with Heritage of Success
Proven Leadership with Heritage of Success Christopher Hall Karin Eastham Richard Chen, MD Chief Executive Officer Board Chair President, Chief Medical Officer Over 20 years experience Over 35 years of experience Physician-scientist with over 20 years building life sciences companies guiding financi
Slide 16: Strategic Investment from Industry Leaders Anchor Our Business
Strategic Investment from Industry Leaders Anchor Our Business CLINICAL BIOPHARMA $86 AI and precision medicine Global oncology leader; leader; partnering to provide partnering on treatments that NeXT Personal to US rely on Personalis tumor oncologists and doctors MM analysis Invested in 2024 | Pers
Slide 17: Strong Cash Position and No Significant Debt
Strong Cash Position and No Significant Debt $22.4MM Revenue for Q2-2026 ~$213MM Cash balance at Jun 30, 2026; no significant debt | Personalis, Inc. | Confidential and Proprietary 17